International Stem Cell (ISCO) Depreciation & Amortization (CF) (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Depreciation & Amortization (CF) of $54000.0 for Q4 2025, little changed year-over-year from $54000.0 in Q4 2024, and down 3.57% quarter-over-quarter from $56000.0 in Q3 2025.
International Stem Cell (ISCO) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $54000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) changed 0.0% year-over-year to $54000.0; the TTM figure through Dec 2025 stood at $219000.0 (up 6.31% YoY), while the FY2025 annual figure was $219000.0, up 6.31% from the prior year.
- Depreciation & Amortization (CF) declined to $54000.0 in Q4 2025 per ISCO's latest filing, from $56000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $67000.0 in Q4 2021 and bottomed at $47000.0 in Q3 2023.
- Historically, Depreciation & Amortization (CF) has averaged $54950.0 across 5 years, with a median of $54000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) fell 22.39% — and 2024, when it gained 12.77%.
- International Stem Cell's Depreciation & Amortization (CF) stood at $67000.0 in 2021, then dropped by 22.39% to $52000.0 in 2022, then slipped by 7.69% to $48000.0 in 2023, then increased by 12.5% to $54000.0 in 2024, then changed by 0.0% to $54000.0 in 2025.
- Business Quant data shows ISCO's Depreciation & Amortization (CF) at $54000.0 in Q4 2025, $56000.0 in Q3 2025, and $54000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | 28,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28,000.00 |
| Jun 30, 2026 | 28,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 54,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 48,000.00 |
| Dec 31, 2023 | 48,000.00 |